Broderick Meaghan, Tripodi Gianluca, Dwyer Kevin
Department of Surgery, Stamford Hospital, Stamford, CT, USA.
Am Surg. 2024 Apr;90(4):691-694. doi: 10.1177/00031348231206582. Epub 2023 Oct 18.
Ground level falls in the elderly often lead to complications due to use of anticoagulants (ACs). Intracranial hemorrhage (ICH), immediate or delayed, is a feared consequence of such falls. The rate of delayed ICH (dICH) in patients taking anticoagulants or antiplatelet (AP) agents ranges from .6% to 6%. Patients on warfarin have a persistent rate of dICH, leading to implementation of routine repeat head CTs at our institution. This policy was extended to direct oral anticoagulants (DOACs). This study aims to determine institutional incidence of DOAC-associated dICH.
With IRB waiver approval, we conducted a retrospective review of trauma evaluations for falls on DOACs from 2016 to 2018. We reviewed records for neurologic status, DOAC use, and results of initial and delayed head CTs. Exclusion criteria included initial GCS ≤14, new neurologic deficits, traumatic findings on initial CT, concurrent use of additional AC/AP, or absence of repeat head CT.
Among 632 patients evaluated for falls on AC/AP therapy, 159 (25%) of patients were included in the review. The age range was 19-98 years old, with 99 females and 60 males. Half of the patients were on apixaban, with the rest on dabigatran or rivaroxaban. Ten patients presented with GCS of 14. No delayed hemorrhages were detected in this population.
The necessity of a repeat head CT in patients taking DOACs is debated in the literature. Our analysis failed to demonstrate any delayed hemorrhage in neurologically intact patients after head strike on DOAC, suggesting no indication for follow-up imaging in this group.
老年人因使用抗凝剂(ACs)导致的平地跌倒常引发并发症。颅内出血(ICH),无论是即时性还是延迟性,都是此类跌倒令人担忧的后果。服用抗凝剂或抗血小板(AP)药物的患者中延迟性颅内出血(dICH)的发生率在0.6%至6%之间。服用华法林的患者dICH发生率持续存在,这导致我们机构实施常规重复头部CT检查。该政策已扩展至直接口服抗凝剂(DOACs)。本研究旨在确定DOAC相关dICH的机构发生率。
经机构审查委员会(IRB)豁免批准,我们对2016年至2018年因服用DOACs而跌倒的创伤评估进行了回顾性研究。我们审查了神经功能状态、DOAC使用情况以及初始和延迟头部CT的结果记录。排除标准包括初始格拉斯哥昏迷量表(GCS)≤14、新出现的神经功能缺损、初始CT上的创伤性表现、同时使用其他AC/AP或未进行重复头部CT检查。
在632例接受AC/AP治疗跌倒评估的患者中,159例(25%)纳入本研究。年龄范围为19至98岁,其中女性99例,男性60例。一半患者服用阿哌沙班,其余服用达比加群或利伐沙班。10例患者初始GCS评分为14。该人群中未检测到延迟性出血。
文献中对于服用DOACs的患者重复进行头部CT检查的必要性存在争议。我们的分析未能证明服用DOACs的患者头部撞击后神经功能完好的患者出现任何延迟性出血,表明该组患者无需进行后续影像学检查。